Abbonarsi

Atrial fibrillation is a marker of increased mortality risk in nonischemic heart failure—Results from the DANISH trial - 23/01/21

Doi : 10.1016/j.ahj.2020.10.073 
Rune Boas, MD a, b, , Jens Jakob Thune, MD, PhD b, c, Steen Pehrson, MD, DMSc b, d, Lars Køber, MD, DMSc b, d, Jens C. Nielsen, MD, DMSc e, Lars Videbæk, MD, PhD f, Jens Haarbo, MD, DMSc g, Eva Korup, MD, PhD h, Niels Eske Bruun, MD, DMSc b, i, Axel Brandes, MD f, Hans Eiskjær, MD, DMSc e, Anna M. Thøgersen, MD, PhD h, Berit T. Philbert, MD d, Jesper Hastrup Svendsen, MD, DMSc b, d, Ulrik Dixen, MD, PhD a, b
a Department of Cardiology, Amager Hvidovre University Hospital, University of Copenhagen, Copenhagen, Denmark 
b Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark 
c Department of Cardiology, Bispebjerg Frederiksberg University Hospital, University of Copenhagen, Copenhagen, Denmark 
d Department of Cardiology, Rigshospitalet, Copenhagen, Denmark 
e Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark 
f Department of Cardiology, Odense University Hospital, Odense, Denmark 
g Department of Cardiology, Herlev Gentofte University Hospital, Copenhagen, Denmark 
h Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark 
i Department of Cardiology, Zealand University Hospital, Roskilde, Denmark 

Reprint requests: Rune Boas, MD, Department of Cardiology, Hvidovre Hospital, Kettegaard Alle 30, Hvidovre 2650, DenmarkDepartment of CardiologyHvidovre HospitalKettegaard Alle 30Hvidovre2650Denmark

Riassunto

Background

Atrial fibrillation (AF) in heart failure (HF) patients has been associated with a worse outcome. Similarly, excessive supraventricular ectopic activity (ESVEA) has been linked to development of AF, stroke, and death. This study aimed to investigate AF and ESVEA's association with outcomes and effect of prophylactic implantable cardioverter defibrillator (ICD) implantation in nonischemic HF patients.

Methods

A total of 850 patients with nonischemic HF, left ventricle ejection fraction ≤35%, and elevated N-terminal pro-brain natriuretic peptides underwent 24 hours Holter recording. The presence of AF (≥30 seconds) and ESVEA (≥30 supraventricular ectopic complexes (SVEC) per hour or run of SVEC ≥20 beats) were registered. Outcomes were all-cause mortality, cardiovascular death (CVD), and sudden cardiac death (SCD).

Results

AF was identified in 188 patients (22%) and ESVEA in 84 patients (10%). After 4 years and 11 months of follow-up, a total of 193 patients (23%) had died. AF was associated with all-cause mortality (hazard ratio [HR] 1.44; confidence interval [CI] 1.04-1.99; P = .03) and CVD (HR 1.59; CI 1.07-2.36; P = .02). ESVEA was associated with all-cause mortality (HR 1.73; CI 1.16-2.57; P = .0073) and CVD (HR 1.76; CI 1.06-2.92; P = .03). Neither AF nor ESVEA was associated with SCD. ICD implantation was not associated with an improved prognosis for neither AF (P value for interaction = .17), nor ESVEA (P value for interaction = .68).

Conclusions

Both AF and ESVEA were associated with worsened prognosis in nonischemic HF. However, ICD implantation was not associated with an improved prognosis for either group.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Funding: This study was supported by The Danish Heart Foundation (grant number 17-R116-A7647-22064) and by The Hospital's Independent Research Funds, Copenhagen University Hospital Amager and Hvidovre, Denmark. Neither funds have had any influence on the design, conduct, analyses, or publications of the study.


© 2020  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 232

P. 61-70 - Febbraio 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Levothyroxine dose and risk of atrial fibrillation: A nested case-control study
  • Inna Y. Gong, Clare L. Atzema, Iliana C. Lega, Peter C. Austin, Yingbo Na, Paula A. Rochon, Lorraine L. Lipscombe
| Articolo seguente Articolo seguente
  • Shock in the cardiac intensive care unit: Changes in epidemiology and prognosis over time
  • Jacob C. Jentzer, Abdelrahman M. Ahmed, Saraschandra Vallabhajosyula, Barry Burstein, Meir Tabi, Gregory W. Barsness, Joseph G. Murphy, Patricia J. Best, Malcolm R. Bell

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.